Shares of Pain Therapeutics (NASDAQ:PTIE) reached a new 52-week high during mid-day trading on Friday . The company traded as high as $2.72 and last traded at $2.64, with a volume of 254,050 shares changing hands. The stock had previously closed at $2.55.

Separately, Zacks Investment Research lowered Pain Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, May 4th.

The stock’s 50 day moving average price is $2.18 and its 200-day moving average price is $2.08. The firm’s market capitalization is $122.27 million.

Pain Therapeutics (NASDAQ:PTIE) last posted its quarterly earnings data on Tuesday, July 19th. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.07. Equities research analysts expect that Pain Therapeutics will post ($0.54) EPS for the current fiscal year.

Pain Therapeutics, Inc is a biopharmaceutical company. The Company is focused on drug development efforts on disorders of the nervous system, such as chronic pain. The Company’s lead drug candidate, REMOXY, is an abuse-deterrent, oral formulation of oxycodone (CII). The Company’s other products is FENROCK.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.